Furthermore, our in vitro and in vivo results revealed that RFPL3 knockdown inhibited lung cancer cell growth and the genetic–clinicopathologic correlation analysis found that upregulation of RFPL3 was significantly associated with shorter OS of patients with lung adenocarcinomas. The gene discussed is RFPL3; the disease is lung cancer.